Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

Track Pfizer share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, shareholding, financial reports, annual & quarterly results, and profit & loss ...

Pfizer (PFE) is back in focus for investors as its latest reported figures offer a snapshot of how the US$143.7b ...

Pfizer (NYSE:PFE) has been dismissed as a defendant in a major federal lawsuit alleging generic drug price fixing. The court ...

Get the live share price of Pfizer Inc (PFE), including intraday charts, historical performance, key financials, and market ...

Pfizer is rated a Buy with 55%+ upside potential, driven by a robust pipeline and undervalued forward earnings. Read more on ...

Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product and patent cliff challenges could prevent a big bounce this year. Even if ...

I last covered Pfizer Inc. stock (NYSE:PFE) on Feb 19. The article rated the stock as hold after examining its FQ4 earnings report (ER) and dividend declarations. Since then, a few new catalysts have ...

Pfizer shares have emerged as a compelling contrarian investment opportunity as the pharmaceutical giant trades at historically attractive valuations following an extended period of market skepticism.

Pfizer Ltd. share price jumped over 6% in Thursday's session as the company reported an increase in its net profit during July–September. Pfizer's bottom line increased 19.4% on the year to Rs 189 ...

PFE is betting on monthly obesity treatments and new oral programs to challenge LLY and NVO in a market projected to hit $120 billion by 2035.